Abstract:Background: DExD-box helicase 21 (DDX21) is an essential member of the RNA helicase family. DDX21 is involved in the carcinogenesis of various malignancies, but there has been no comprehensive research on its involvement in different types of cancer. Method: This study used TCGA, CPTAC, GTEx, GEO, FANTOM5, BioGRID, TIMER2, GEPIA2, cBioPortal, STRING, and Metascape databases and Survival ROC software to evaluate DDX21 gene expression, protein expression, immunohistochemistry, gene mutation, immune infiltration, and protein phosphorylation in 33 TCGA tumor types, as well as the prognostic relationship between DDX21 and different tumors, by survival analysis and similar gene enrichment analysis. Furthermore, Cell Counting Kit-8 (CCK-8) and Transwell studies were employed to assess the effect of DDX21 expression on lung adenocarcinoma (LUAD) cell proliferation and migration. Result: The DDX21 gene was highly expressed in most cancers, and overexpression was associated with poor overall survival (OS) and disease-free survival (DFS). DDX21 mutations were most common in uterine corpus endometrial carcinoma (UCEC; >5%), and DDX21 expression was positively correlated with the degree of infiltration of CAF and CD8 + cells in several tumor types. Numerous genes were co-expressed with DDX21. Gene enrichment analysis revealed close links between DDX21, RNA metabolism, and ribosomal protein production. In vitro analysis of LUAD cells showed that DDX21 expression was positively correlated with cell proliferation and migration capacity, consistent with prior bioinformatics studies. Conclusions: DDX21 is overexpressed in a variety of cancers, and overexpression in some cancers is associated with poor prognosis. Immune infiltration and DDX21-related gene enrichment analyses indicated that DDX21 may affect cancer development through mechanisms that regulate tumor immunity, RNA metabolism, and ribosomal protein synthesis. This pan-cancer study revealed the prognostic value and the oncogenic role of DDX21.

DDX47 promotes cell proliferation and migration in lung adenocarcinoma

DDX17 Promotes the Growth and Metastasis of Lung Adenocarcinoma

DDX18 Facilitates the Tumorigenesis of Lung Adenocarcinoma by Promoting Cell Cycle Progression through the Upregulation of CDK4

The DEAD-box RNA helicase 51 controls non-small cell lung cancer proliferation by regulating cell cycle progression via multiple pathways

DLX1 acts as a novel prognostic biomarker involved in immune cell infiltration and tumor progression in lung adenocarcinoma

DEAD-Box Helicase 3 X-Linked Promotes Metastasis by Inducing Epithelial-Mesenchymal Transition via p62/Sequestosome-1

DEAD-box helicase 27 plays a tumor-promoter role by regulating the stem cell-like activity of human colorectal cancer cells.

DEAD-Box Helicase 27 Triggers Epithelial to Mesenchymal Transition by Regulating Alternative Splicing of Lipoma-Preferred Partner in Gastric Cancer Metastasis.

Knockdown of DDX46 Inhibits Proliferation and Induces Apoptosis in Esophageal Squamous Cell Carcinoma Cells.

DMBX1 Promotes Tumor Proliferation and Regulates Cell Cycle Progression Via Repressing OTX2-mediated Transcription of P21 in Lung Adenocarcinoma Cell.

DDX41 Regulates the Expression and Alternative Splicing of Genes Involved in Tumorigenesis and Immune Response

DDX55 promotes hepatocellular carcinoma progression by interacting with BRD4 and participating in exosome-mediated cell-cell communication.

Pan-cancer analysis identifies RNA helicase DDX1 as a prognostic marker

DDX21 Interacts with WDR5 to Promote Colorectal Cancer Cell Proliferation by Activating CDK1 Expression

Lentiviral DDX46 knockdown inhibits growth and induces apoptosis in human colorectal cancer cells.

DDX39 Promotes Hepatocellular Carcinoma Growth and Metastasis Through Activating Wnt/β-catenin Pathway

DDX39B contributes to the proliferation of colorectal cancer through direct binding to CDK6/CCND1

DEAD-box Helicase 27 Promotes Hepatocellular Carcinoma Progression Through ERK Signaling

Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types

DDX5 and DDX17—multifaceted proteins in the regulation of tumorigenesis and tumor progression

LINC00908 promotes malignant progression and glycolysis in lung adenocarcinoma via interactions with DDX54 and RFX2